<code id='3B3039C714'></code><style id='3B3039C714'></style>
    • <acronym id='3B3039C714'></acronym>
      <center id='3B3039C714'><center id='3B3039C714'><tfoot id='3B3039C714'></tfoot></center><abbr id='3B3039C714'><dir id='3B3039C714'><tfoot id='3B3039C714'></tfoot><noframes id='3B3039C714'>

    • <optgroup id='3B3039C714'><strike id='3B3039C714'><sup id='3B3039C714'></sup></strike><code id='3B3039C714'></code></optgroup>
        1. <b id='3B3039C714'><label id='3B3039C714'><select id='3B3039C714'><dt id='3B3039C714'><span id='3B3039C714'></span></dt></select></label></b><u id='3B3039C714'></u>
          <i id='3B3039C714'><strike id='3B3039C714'><tt id='3B3039C714'><pre id='3B3039C714'></pre></tt></strike></i>

          explore

          explore

          author:comprehensive    Page View:262
          Vertex Pharmaceuticals Inc. building
          Craig F. Walker/The Boston Globe

          Vertex Pharmaceuticals said Friday that, over a year after receiving the company’s stem-cell therapy, two type 1 diabetes patients no longer need to take insulin injections and saw stark reductions in a biological marker of disease. 

          The results, presented at the American Diabetes Association conference in San Diego, bolstered experts’ hopes that the treatment could provide a functional cure for some patients. In 2021, Vertex announced dramatic results from the first man to receive the treatment, but researchers cautioned it was just one person, who had only been followed for 90 days.

          advertisement

          “The data look as good as they could be,” said Jeanne Loring, a stem cell expert and professor emeritus at Scripps Research not involved in the work, in an email.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          comprehensive

          Novavax promises a turnaround & Lilly roils the obesity market
          Novavax promises a turnaround & Lilly roils the obesity market

          SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

          read more
          STAT's 2023 biotech VC rankings: ARCH Venture Partners tops list
          STAT's 2023 biotech VC rankings: ARCH Venture Partners tops list

          AdobeThisarticleisadaptedfromthe2023editionofSTAT’sannualreport,“Rankingbiotech’stopventurecapitalfi

          read more
          In age of alternative facts, a scholarly course on calling out crap
          In age of alternative facts, a scholarly course on calling out crap

          Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

          read more

          The PBM ad wars are taking over Washington, D.C.

          AdobeWASHINGTON–Ifyouliveinthiscity,you’reprobablyawashinpharmacybenefitmanagerads—whetheryou’relist